• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过肿瘤脉管系统控制免疫细胞进入:优化黑色素瘤免疫治疗中缺失的环节?

Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?

作者信息

Tan Lih Yin, Martini Carmela, Fridlender Zvi G, Bonder Claudine S, Brown Michael P, Ebert Lisa M

机构信息

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia.

出版信息

Clin Transl Immunology. 2017 Mar 17;6(3):e134. doi: 10.1038/cti.2017.7. eCollection 2017 Mar.

DOI:10.1038/cti.2017.7
PMID:28435677
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5382436/
Abstract

Metastatic melanoma remains a fatal disease to many worldwide, even after the breakthrough introduction of targeted therapies such as BRAF inhibitors and immune checkpoint blockade therapies such as CTLA-4 and PD-1 inhibitors. With advances in our understanding of this disease, as well as the increasing data gathered from patient studies, the significance of the host immune response to cancer progression and response to treatment is becoming clear. More specifically, the presence of intratumoral CD8 cytotoxic T-cells correlates with better prognosis whereas the accumulation of monocytes/macrophages and neutrophils in the tumour is often associated with worse prognosis. Access and infiltration of circulating leukocytes into the tumour is governed by adhesion molecules and chemokines expressed by the endothelial cells of the vasculature. This review focuses on the adhesion molecules and chemokines which control the homing of CD8 cytotoxic T-cells, monocytes and neutrophils to peripheral tissues, including tumours. We discuss the role of these leukocyte subsets in regulating melanoma growth, and detail the mechanisms used by tumours to selectively recruit or exclude these leukocytes for their own advantage. In doing so, we bring to light an underappreciated component of tumour biology which should be considered in combination with current treatments to selectively alter the leukocyte composition of tumours and ultimately enhance treatment outcome.

摘要

转移性黑色素瘤对全球许多人来说仍然是一种致命疾病,即使在引入了如BRAF抑制剂等靶向治疗以及如CTLA-4和PD-1抑制剂等免疫检查点阻断疗法之后。随着我们对这种疾病理解的进步,以及从患者研究中收集到的数据不断增加,宿主免疫反应对癌症进展和治疗反应的重要性正变得清晰。更具体地说,肿瘤内CD8细胞毒性T细胞的存在与较好的预后相关,而肿瘤中单核细胞/巨噬细胞和中性粒细胞的积累通常与较差的预后相关。循环白细胞进入肿瘤的过程受血管内皮细胞表达的黏附分子和趋化因子的调控。本综述聚焦于控制CD8细胞毒性T细胞、单核细胞和中性粒细胞归巢至外周组织(包括肿瘤)的黏附分子和趋化因子。我们讨论了这些白细胞亚群在调节黑色素瘤生长中的作用,并详细阐述了肿瘤为自身利益选择性招募或排除这些白细胞所采用的机制。通过这样做,我们揭示了肿瘤生物学中一个未得到充分重视的组成部分,应将其与当前治疗方法结合考虑,以选择性地改变肿瘤中的白细胞组成,最终提高治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9aa/5382436/e8dfb297d5d7/cti20177f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9aa/5382436/189e42067068/cti20177f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9aa/5382436/e8dfb297d5d7/cti20177f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9aa/5382436/189e42067068/cti20177f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9aa/5382436/e8dfb297d5d7/cti20177f2.jpg

相似文献

1
Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?通过肿瘤脉管系统控制免疫细胞进入:优化黑色素瘤免疫治疗中缺失的环节?
Clin Transl Immunology. 2017 Mar 17;6(3):e134. doi: 10.1038/cti.2017.7. eCollection 2017 Mar.
2
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂:黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
3
Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.转移性黑色素瘤患者治疗中的靶向治疗与免疫检查点抑制剂:病理学家指南及更新
Pathology. 2016 Feb;48(2):194-202. doi: 10.1016/j.pathol.2015.12.010. Epub 2016 Jan 20.
4
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.血管靶向以提高癌症免疫检查点阻断的效率。
Front Immunol. 2018 Dec 21;9:3081. doi: 10.3389/fimmu.2018.03081. eCollection 2018.
5
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.黑色素瘤研究的未来展望:“黑色素瘤桥梁”会议报告:那不勒斯,2014年12月3日至6日
J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.
6
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.联合抗 CTLA-4 加抗 PD-1 检查点阻断利用了与单药治疗部分不同的细胞机制。
Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22699-22709. doi: 10.1073/pnas.1821218116. Epub 2019 Oct 21.
7
Molecular genetic and immunotherapeutic targets in metastatic melanoma.转移性黑色素瘤的分子遗传学和免疫治疗靶点
Virchows Arch. 2017 Aug;471(2):281-293. doi: 10.1007/s00428-017-2113-3. Epub 2017 Mar 29.
8
Immunotherapy in melanoma: Recent advances and future directions.黑色素瘤的免疫疗法:最新进展与未来方向。
Eur J Surg Oncol. 2017 Mar;43(3):604-611. doi: 10.1016/j.ejso.2016.07.145. Epub 2016 Sep 2.
9
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.放疗和双重检查点阻断激活癌症中的非冗余免疫机制。
Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.
10
Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma.PD-1/CTLA-4联合检查点阻断治疗转移性黑色素瘤患者后成功治疗重症肌无力
Front Oncol. 2019 Feb 14;9:84. doi: 10.3389/fonc.2019.00084. eCollection 2019.

引用本文的文献

1
TGF-β3 promotes vascular normalization of prostate cancer to potentiate immunotherapy and chemotherapy.转化生长因子-β3促进前列腺癌血管正常化以增强免疫治疗和化疗效果。
Cancer Immunol Immunother. 2025 Jul 12;74(8):268. doi: 10.1007/s00262-025-04103-2.
2
Apelin/APJ: Another Player in the Cancer Biology Network.阿片肽/血管紧张素II 1型受体相关蛋白:癌症生物学网络中的另一个参与者。
Int J Mol Sci. 2025 Mar 25;26(7):2986. doi: 10.3390/ijms26072986.
3
Innate Immune Cells in Melanoma: Implications for Immunotherapy.固有免疫细胞在黑色素瘤中的作用:免疫治疗的启示。

本文引用的文献

1
VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.VEGF 中和联合 CTLA-4 阻断改变与增强黑色素瘤淋巴细胞浸润和体液识别相关的可溶性和细胞因子。
Cancer Immunol Res. 2016 Oct;4(10):858-868. doi: 10.1158/2326-6066.CIR-16-0084. Epub 2016 Aug 22.
2
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.一项评估威罗菲尼(vemurafenib)继以伊匹单抗(ipilimumab)治疗未经治 BRAF 突变转移性黑色素瘤患者的 II 期研究。
J Immunother Cancer. 2016 Aug 16;4:44. doi: 10.1186/s40425-016-0148-7. eCollection 2016.
3
Int J Mol Sci. 2024 Aug 5;25(15):8523. doi: 10.3390/ijms25158523.
4
Single-cell adhesive profiling in an optofluidic device elucidates CD8 T lymphocyte phenotypes in inflamed vasculature-like microenvironments.光流控装置中的单细胞黏附分析揭示了炎症性血管样微环境中的CD8 T淋巴细胞表型。
Cell Rep Methods. 2024 Apr 22;4(4):100743. doi: 10.1016/j.crmeth.2024.100743. Epub 2024 Mar 29.
5
A Fucose-Containing Sulfated Polysaccharide from Spatoglossum schröederi Potentially Targets Tumor Growth Rather Than Cytotoxicity: Distinguishing Action on Human Melanoma Cell Lines.施氏拟乌贼含岩藻糖硫酸多糖可能针对肿瘤生长而非细胞毒性:对人黑色素瘤细胞系的区分作用。
Mar Biotechnol (NY). 2024 Feb;26(1):181-198. doi: 10.1007/s10126-024-10287-y. Epub 2024 Jan 26.
6
Vasculogenic mimicry structures in melanoma support the recruitment of monocytes.黑色素瘤中的血管生成拟态结构支持单核细胞的募集。
Oncoimmunology. 2022 Mar 9;11(1):2043673. doi: 10.1080/2162402X.2022.2043673. eCollection 2022.
7
Endothelial cell-derived Apelin inhibits tumor growth by altering immune cell localization.内皮细胞源性Apelin通过改变免疫细胞定位来抑制肿瘤生长。
Sci Rep. 2021 Jul 7;11(1):14047. doi: 10.1038/s41598-021-93619-5.
8
Green Propolis Compounds (Baccarin and p-Coumaric Acid) Show Beneficial Effects in Mice for Melanoma Induced by B16f10.绿色蜂胶化合物(紫铆因和对香豆酸)对B16f10诱导的小鼠黑色素瘤显示出有益作用。
Medicines (Basel). 2021 Apr 30;8(5):20. doi: 10.3390/medicines8050020.
9
Evolution of delayed resistance to immunotherapy in a melanoma responder.黑色素瘤应答者免疫治疗后迟发性耐药的演变。
Nat Med. 2021 Jun;27(6):985-992. doi: 10.1038/s41591-021-01331-8. Epub 2021 May 3.
10
Identification of Four Genes as Prognosis Signatures in Lung Adenocarcinoma Microenvironment.鉴定四个基因作为肺腺癌微环境中的预后标志物
Pharmgenomics Pers Med. 2021 Jan 8;14:15-26. doi: 10.2147/PGPM.S283414. eCollection 2021.
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
转移性黑色素瘤中联合 BRAF 和 MEK 抑制的耐药性:下一步该怎么办?
Eur J Cancer. 2016 Jul;62:76-85. doi: 10.1016/j.ejca.2016.04.005. Epub 2016 May 24.
4
Platelets Guide Leukocytes to Their Sites of Extravasation.血小板引导白细胞至其渗出部位。
PLoS Biol. 2016 May 6;14(5):e1002459. doi: 10.1371/journal.pbio.1002459. eCollection 2016 May.
5
CANCER IMMUNOLOGY. The "cancer immunogram".癌症免疫学。“癌症免疫图谱”。
Science. 2016 May 6;352(6286):658-60. doi: 10.1126/science.aaf2834.
6
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.GD2特异性嵌合抗原受体T细胞在遇到抗原后会经历强烈的激活和清除,但可通过程序性死亡蛋白1(PD-1)阻断来保护其免受激活诱导的细胞死亡。
Mol Ther. 2016 Jun;24(6):1135-1149. doi: 10.1038/mt.2016.63. Epub 2016 Mar 29.
7
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.促进肿瘤微环境中的 T 细胞浸润克服对 PD-L1 阻断的抵抗。
Cancer Cell. 2016 Mar 14;29(3):285-296. doi: 10.1016/j.ccell.2016.02.004.
8
Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis.肿瘤血管生成拟态预测癌症患者预后不良:一项荟萃分析。
Angiogenesis. 2016 Apr;19(2):191-200. doi: 10.1007/s10456-016-9500-2. Epub 2016 Feb 22.
9
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.淋巴细胞中的趋化因子受体模式反映了黑色素瘤的转移扩散情况。
J Clin Invest. 2016 Mar 1;126(3):921-37. doi: 10.1172/JCI80071. Epub 2016 Feb 8.
10
Tumor cell vascular mimicry: Novel targeting opportunity in melanoma.肿瘤细胞血管拟态:黑色素瘤中的新型靶向机遇。
Pharmacol Ther. 2016 Mar;159:83-92. doi: 10.1016/j.pharmthera.2016.01.006. Epub 2016 Jan 22.